Relationships between Markers of Bone Metabolism Used in the Treatment of Osteoporosis

Nagai, Takashi; Sakamoto, Keizo; Munechika, Kennichi; Fujita, Masayori; Tsuchiya, Naoto; Shibuki, Takashi; Inagaki, Kenji

doi:10.15369/sujms.23.165

Cited by 2 publications

(2 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Serum NTX has less diurnal variation than urine NTX but tends to be higher with decreased renal function [ 19 , 20 ]. Because urine NTX requires measurement of the second urine sample early in the morning, if the test is to be performed strictly, it is necessary to give the patient a urine test container in advance [ 21 ]. Since BAP, P1NP, and TRACP-5b have fewer diurnal variations [ 20 ], physicians have started using these tests in their practices.…”

Section: Discussionmentioning

confidence: 99%

“…We conducted our first survey in 2015 to determine how the choice of testing methods and therapeutic agents in osteoporosis practice differs between hospital- and clinic-based orthopaedic surgeons [ 5 ]. The second survey was conducted in 2020 to determine how testing and therapeutic agents in osteoporosis care have changed over the past five years.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Changes in Testing and Treatment Methods in Osteoporosis Care

Nagai,

Ishikawa,

Tsuchiya

et al. 2024

Journal of Osteoporosis

Self Cite

View full text Add to dashboard Cite

Osteoporosis treatment plays a crucial role in preventing fractures, particularly in bedridden patients. We conducted a questionnaire survey presenting hypothetical clinical cases in 2015 and 2020 to investigate trends over a 5-year period. The target population included physicians working in clinics and hospitals within our neighbourhood. The cases were presented, and the questionnaire was administered in a confidential format. The orthopaedic surgeons were matched for age and practice, resulting in 74 cases being included in the analysis. Comparing the 2015 and 2020 results, we observed a notable increase in physicians who would perform “bone mineral density measurements of the lumbar spine and hip.” Furthermore, there was a significant rise in the percentage of respondents willing to test for bone metabolic markers, such as serum type I collagen cross-linked N-telopeptide (NTX), procollagen I N-terminal propeptide (P1NP), and tartrate-resistant acid phosphatase 5b (TRACP-5b). Regarding therapeutic agents, bisphosphonates decreased in usage, whereas parathyroid hormone and romosozumab witnessed an increase. In conclusion, the percentage of physicians requesting bone mineral density measurements of the lumbar spine and hip increased over the five-year period. In addition, more physicians chose to utilise bone metabolic markers due to their ease of measurement through blood tests and reduced diurnal variation. Finally, there was a marked trend towards the administration of drugs capable of rapidly and effectively increasing bone mineral density at an early stage of treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Changes in Testing and Treatment Methods in Osteoporosis Care

Nagai,

Ishikawa,

Tsuchiya

et al. 2024

Journal of Osteoporosis

Self Cite

View full text Add to dashboard Cite

show abstract

Effects of 3 Years of Treatment with a Selective Estrogen Receptor Modulator for Postmenopausal Osteoporosis on Markers of Bone Turnover and Bone Mineral Density

Nagai

Sakamoto

Matsunaga

et al. 2012

Showa Univ J Med Sci

Self Cite

View full text Add to dashboard Cite

: Aim : The aim of the present study was to assess the changes in bone mineral density and bone turnover markers in long-term SERM. Methods : The study was performed on 25 female outpatients with primary osteoporosis treated at the Osteoporosis Department of Showa University School of Medicine. All patients had been on raloxifene 60 mg/day for ≥ 3 years. The mean patient age was 67.1 years and the women were, on average, 18.4 years postmenopausal. Levels of bone turnover markers urinary naltrexone NTX and bone-speci c alkaline phosphatase BAP and bone mineral density BMD ; front lumbar vertebrae, three proximal femur sites, and two distal radius sites were determined before and then annually after starting raloxifene for a period of 3 years. Results : Over the 3-year treatment period, signi cant decreases were seen in both urinary NTX and BAP levels. Although BMD of the lumbar vertebrae and distal radius was increased over the 3 years after initiation of raloxifene treatment, the difference failed to reach statistical signicance. The BMD of the femoral neck decreased, whereas that of the femoral trochanter and femoral intertrochanter area increased. Conclusions : The selective estrogen receptor modulator raloxifene is suitable for the treatment of osteoporosis in postmenopausal patients because it reduces bone turnover while maintaining adequate bone density.

show abstract

Relationships between Markers of Bone Metabolism Used in the Treatment of Osteoporosis

Cited by 2 publications

References 15 publications

Changes in Testing and Treatment Methods in Osteoporosis Care

Changes in Testing and Treatment Methods in Osteoporosis Care

Effects of 3 Years of Treatment with a Selective Estrogen Receptor Modulator for Postmenopausal Osteoporosis on Markers of Bone Turnover and Bone Mineral Density

Contact Info

Product

Resources

About